• If higher-cost generics were swapped out, patients could save 88%

    If costly generics were replaced with cheaper generics that have the same clinical value, total spending could have slimmed by nearly 90 percent, Johns Hopkins researchers found. 
  • Pharmacist shortage could exacerbate low flu vaccination rates

    Since the beginning of the COVID-19 pandemic, flu vaccination rates have slowed — a trend that could be worsened by the nation's pharmacy workforce issue. 
  • 6 drugmakers short on flu drug

    As hospitals tackle an early flu season with viral infections soaring, six drugmakers have reported short supply of oseltamivir, a common flu drug. 
  • 2 Pfizer updates: bivalent booster efficacy and a combo flu, COVID-19 vaccine

    After Pfizer raised its projected COVID-19 vaccine annual revenue to $34 billion, the drugmaker reported positive results for its modified booster and began testing a vaccine candidate intended for COVID-19 and flu. 
  • Common flu drug in high demand

    Prescriptions for Tamiflu (oseltamivir), a popular influenza antiviral, are higher this year than they have been for the last nine flu seasons, according to GoodRx. 
  • New antibiotic for UTIs is ready for FDA approval, company says

    Drug company GSK stopped its new antibiotic drug study a year early and is preparing to submit for FDA approval after finding it effective in treating urinary tract infections, CNN reported Nov. 3.
  • With 282M vaccine jabs, pharmacists saved healthcare $450B, study estimates

    Pharmacist-administered COVID-19 vaccines have averted 1 million U.S. deaths and saved $450 billion in healthcare costs, according to estimates published in the Journal of the American Pharmacists Association. 
  • Europe approves Sanofi's RSV prevention treatment

    The European Commission approved Sanofi and AstraZeneca's respiratory syncytial virus preventive drug Nov. 4 while the U.S. faces a surge and a lack of RSV treatments. 
  • 8 drugmakers' Q3 results: Who's up, down

    As the U.S. approaches an earlier and more severe season of multiple viruses, here's how eight drugmakers ended their third quarter financially:
  • 3 in 4 teens lost weight in obesity drug trial

    After taking an obesity drug each week for more than a year, 73 percent of teenage study participants recorded a weight loss of at least 5 percent. The results were published Nov. 2 in The New England Journal of Medicine.
  • Price of new cancer drugs jumps 53% in 4 years, report finds

    The cost of new cancer drugs taken at home rose more than 25 percent from 2017 to 2021, and the price of all new cancer drugs and infusion treatments jumped 53 percent, according to a Nov. 2 report from California Representative Katie Porter's office. 
  • CVS to drop services provider Omnicare

    CVS Health is "actively exploring strategic alternatives for Omnicare" after recording a pre-tax loss on assets held for sale of $2.5 billion related to the write-down of the long-term care business, according to a Nov. 2 earnings call. 
  • 10 systems seeking pharmacy leaders

    The following 10 hospitals, health systems and hospital operators have posted job listings seeking pharmacy leaders in the last week.
  • Where 6 drugmakers are with RSV vaccine development

    As children's hospitals grapple with intense capacity issues and an increase in patients with respiratory syncytial virus, treatment options are limited. Multiple RSV vaccine candidates are in the works, but the earliest timeline places the first approval next year. 
  • Pfizer CEO explains COVID-19 vaccine price

    In a Nov. 1 earnings call, Pfizer CEO Albert Bourla said "people wouldn't see the difference" with the tentative commercial price for its COVID-19 vaccine, which hovers between $110 and $130 per dose, because the vaccine-maker plans for no copays. 
  • 2 updates on the future of COVID-19 vaccines, treatments

    As vaccine-makers reroute their COVID-19 therapy and vaccine plans for the future of the pandemic, drugmakers are testing potential avenues with human proteins and intranasal options.
  • Drugmakers scramble for entry in Pfizer's $7B pneumonia vaccine market

    Pharmaceutical companies are working to step into the pneumonia vaccine market, which Pfizer currently dominates and is forecasted to generate $10 billion by 2028, The Wall Street Journal reported Oct. 31. 
  • FDA: Prescribing abortion pills to non-pregnant people could be dangerous

    It could be dangerous to offer medication abortion to non-pregnant people and the FDA is concerned, an agency spokesperson told Politico.
  • FDA changes 2007 guidance on hospital use of human cells, tissues

    Hospitals and labs can use human cells, tissues and cellular or tissue-based products — known as HCT/Ps — in nonclinical scientific and educational settings, according to a FDA guidance published Oct. 31 that supersedes its 2007 policy. 
  • 1st RSV vaccine ready to submit for FDA approval, Pfizer says

    Pfizer's maternal respiratory syncytial virus vaccine is ready to submit for FDA approval by the end of the year, CNN reported Nov. 1. 

Featured Whitepapers

Featured Webinars